Radiopharmaceutical needed for prostate cancer patient with metastatic lesions after definitive treatment

Ended Awarded

Contract number
HT009023FG0210050
Awardee
Awarding agency
Obligated
$43,305

Award facts

Contract value 100% obligated
$43,304.64 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
325412 Pharmaceutical Preparation Manufacturing
PSC
6505 Drugs And Biologicals
Set-aside
No set-aside
Competition
Competed under SAP · 1 offer Simplified Acquisition
Pricing
Firm Fixed Price
Place of performance
Sterling, VA, USA

Award details come from SAM.gov/FPDS.

About this award

Written by GovTribe AI ·

Sofie Co., a subsidiary of Sofie Biosciences, Inc., has been awarded a firm fixed price contract valued at forty-three thousand three hundred four dollars and sixty-four cents ($43,304.64) by the Defense Health Agency to provide a radiopharmaceutical needed for a prostate cancer patient with metastatic lesions after definitive treatment. Performance will take place in Sterling, Virginia through September 30, 2023. No set-aside designation was used for this award made under an unspecified blanket purchase agreement call vehicle.

Quick answers

Who was awarded contract HT009023FG0210050?

HT009023FG0210050 was awarded to Sofie CO. by Defense Health Agency (Department of Defense) on February 14, 2023.

How much is contract HT009023FG0210050 worth?

The government has obligated $43,305 on HT009023FG0210050.

Is contract HT009023FG0210050 an order under another contract?

Yes. HT009023FG0210050 is a BPA call under HT001421A0014, a blanket purchase agreement.

Was contract HT009023FG0210050 competed?

The extent of competition for HT009023FG0210050 was competed under sap. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login